Western Standard LLC Graphite Bio, Inc. Transaction History

Western Standard LLC

  • $106 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$2.47 - $3.38 $791,165 - $1.08 Million
-320,310 Reduced 64.66%
175,083 $455,000
Q1 2023

May 15, 2023
BUY
$1.85 - $3.21 $916,477 - $1.59 Million
495,393 New
495,393 $1.21 Million

Others Institutions Holding GRPH

# of Institutions
3
Shares Held
637K
Call Options Held
0
Put Options Held
0
View Full List

About Graphite Bio, Inc.

GRPH Quotes by TradingView
  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track This Portfolio

Track Western Standard LLC Portfolio

Follow Western Standard LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Western Standard LLC, based on Form 13F filings with the SEC.

News

Stay updated on Western Standard LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email